文献速递瓣膜病与结构性心脏病

ApoCIII-Lp(a)复合物联合Lp(a)-OxPL可预测主动脉瓣狭窄快速进展

ApoCIII-Lp(a) complexes in conjunction with Lp(a)-OxPL predict rapid progression of aortic stenosis.
PubMed 文献 · Heart · 2020-02-13

本研究在68例主动脉瓣叶病理分级1-4级患者中免疫染色检测ApoC-III,并在ASTRONOMER试验218例轻中度AS患者中检测循环ApoCIII-Lp(a)复合物水平。结果显示ApoCIII-Lp(a)与Lp(a)、OxPL-apoB或OxPL-apo(a)联合可识别AS快速进展及AVR/心源性死亡风险更高的患者。

要点

  • ApoC-III存在于Lp(a)及主动脉瓣叶中
  • ApoCIII-Lp(a)与Lp(a)同处最高三分位者AS进展更快、AVR/心源性死亡风险更高
  • OxPL-apoB和OxPL-apo(a)呈现类似结果

核心结论

  • ApoC-III存在于Lp(a)和主动脉瓣叶中。
  • ApoCIII-Lp(a)复合物联合Lp(a)、OxPL-apoB或OxPL-apo(a)升高可识别轻中度AS快速进展及AVR/心源性死亡风险更高的患者。

研究设计与样本

  • 对68例主动脉瓣叶病理分级1-4级患者的离体瓣叶行ApoC-III免疫染色。
  • 在ASTRONOMER试验218例轻中度AS患者中检测循环ApoCIII-Lp(a)复合物水平。
  • 对纯化Lp(a)行蛋白质组学分析以确认apoC-III存在。

主要发现

  • 免疫组化显示ApoC-III在所有瓣叶病变严重程度分级中均显著。
  • ApoCIII-Lp(a)与Lp(a)、OxPL-apoB或OxPL-apo(a)同处最高三分位者年化Vpeak显著更高(p<0.001)。
  • 上述组别AVR/心源性死亡风险更高(p=0.03)。
  • ApoB上的ATX及Lp(a)上的ATX与AS快速进展无关联。
  • 蛋白质组学分析显示apoC-III显著存在于纯化Lp(a)上。

关键数值与推荐

  • ApoCIII-Lp(a)与Lp(a)同处最高三分位者年化Vpeak显著更高(p<0.001)。
  • ApoCIII-Lp(a)与Lp(a)同处最高三分位者AVR/心源性死亡风险更高(p=0.03)。
  • ApoCIII-Lp(a)与Lp(a)、OxPL-apoB或OxPL-apo(a)交互作用与年化Vpeak相关(均p<0.05)。

临床怎么用

  • 对轻中度AS患者可检测ApoCIII-Lp(a)联合Lp(a)或OxPL以识别快速进展高危人群。
  • 高危患者可能需要更密切的超声随访监测AS进展。

局限性

  • ApoCIII-Lp(a)检测仅在ASTRONOMER试验218例轻中度AS患者中完成。
  • 瓣叶免疫染色仅纳入68例患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: This study assessed whether apolipoprotein CIII-lipoprotein(a) complexes (ApoCIII-Lp(a)) associate with progression of calcific aortic valve stenosis (AS). METHODS: Immunostaining for ApoC-III was performed in explanted aortic valve leaflets in 68 patients with leaflet pathological grades of 1-4. Assays measuring circulating levels of ApoCIII-Lp(a) complexes were measured in 218 patients with mild-moderate AS from the AS Progression Observation: Measuring Effects of Rosuvastatin (ASTRONOMER) trial. The progression rate of AS, measured as annualised changes in peak aortic jet velocity (Vpeak), and combined rates of aortic valve replacement (AVR) and cardiac death were determined. For further confirmation of the assay data, a proteomic analysis of purified Lp(a) was performed to confirm the presence of apoC-III on Lp(a). RESULTS: Immunohistochemically detected ApoC-III was prominent in all grades of leaflet lesion severity. Significant interactions were present between ApoCIII-Lp(a) and Lp(a), oxidised phospholipids on apolipoprotein B-100 (OxPL-apoB) or on apolipoprotein (a) (OxPL-apo(a)) with annualised Vpeak (all p<0.05). After multivariable adjustment, patients in the top tertile of both apoCIII-Lp(a) and Lp(a) had significantly higher annualised Vpeak (p<0.001) and risk of AVR/cardiac death (p=0.03). Similar results were noted with OxPL-apoB and OxPL-apo(a). There was no association between autotaxin (ATX) on ApoB and ATX on Lp(a) with faster progression of AS. Proteomic analysis of purified Lp(a) showed that apoC-III was prominently present on Lp(a). CONCLUSION: ApoC-III is present on Lp(a) and in aortic valve leaflets. Elevated levels of ApoCIII-Lp(a) complexes in conjunction with Lp(a), OxPL-apoB or OxPL-apo(a) identify patients with pre-existing mild-moderate AS who display rapid progression of AS and higher rates of AVR/cardiac death. TRIAL REGISTRATION: NCT00800800.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Capoulade R, Torzewski M, Mayr M, et al. ApoCIII-Lp(a) complexes in conjunction with Lp(a)-OxPL predict rapid progression of aortic stenosis. Heart. 2020. PMID: 32054669. doi:10.1136/heartjnl-2019-315840

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。